Dany Habr

Dany Habr

UNVERIFIED PROFILE

Are you Dany Habr?   Register this Author

Register author
Dany Habr

Dany Habr

Publications by authors named "Dany Habr"

Are you Dany Habr?   Register this Author

37Publications

1064Reads

19Profile Views

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Leuk Res 2017 05 31;56:52-59. Epub 2017 Jan 31.

CRIMM-Center of Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi and University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.01.032DOI Listing
May 2017

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

N Engl J Med 2015 Jan;372(5):426-35

From Azienda Ospedaliera-Universitaria Careggi, University of Florence, Florence (A.M.V.), Ospedale di Circolo e Fondazione Macchi, Varese (F. Passamonti), and University of Naples Federico II, Naples (F. Pane) - all in Italy; Hôpital Saint-Louis et Université Paris Diderot, Paris (J.J.K.); Johannes Wesling Clinic, Minden, Germany (M.G.); St. István and St. László Hospital and Semmelweis University, Budapest, Hungary (T.M.); Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia (S.D.); Guy's and St. Thomas' NHS Foundation Trust, London (C.N.H.); Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium (P.Z.); Mayo Clinic Cancer Center, Scottsdale, AZ (R.M.); Incyte, Wilmington, DE (S.H., M.M.J., W.G.); Novartis Pharmaceuticals, East Hanover, NJ (J.L., D.H.); Novartis Pharma, Basel, Switzerland (U.P.); and University of Texas M.D. Anderson Cancer Center, Houston (S.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1409002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358820PMC
January 2015

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

Blood 2010 Oct 21;116(14):2448-54. Epub 2010 Jun 21.

Division of Hematology, Department of Internal Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-01-26
Publisher Site
http://dx.doi.org/10.1182/blood-2010-01-261289DOI Listing
October 2010

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.

Br J Haematol 2009 Dec 18;147(5):752-9. Epub 2009 Sep 18.

Department of Internal Medicine, Haematology-Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07908.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779992PMC
December 2009

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.

Eur J Haematol 2009 Jun 28;82(6):458-65. Epub 2009 Jan 28.

Department of Internal Medicine, Hematology, Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2009.01228.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730551PMC
June 2009

Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial.

Ann Hematol 2006 Sep 8;85(9):605-9. Epub 2006 Jul 8.

Department of Internal Medicine, American University of Beirut-Medical Center, P.O. Box 113-0236, Riad El-Solh St., 1107-2020 Beirut, Lebanon.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-006-0136-yDOI Listing
September 2006